Pfizer delayed EUA application
to influence an election
First reported by Dr Jeyanthi Kunadhasan in July 2023 – Report 76
Investigation started in Jan 2025 by Acting US Attorney Ed Martin opened up an inquiry following reporting in the Wall Street Journal about a statement from Glaxo Smith Kline (GSK) and its Global Head of Vaccines, Philip Dormitzer.
“My Pfizer colleagues and I did everything we could to get the FDA’s Emergency Use Authorization at the very first possible moment. Any other interpretation of my comments about the pace of the vaccine’s development would be incorrect,” he told Reuters in a statement.
Further in-depth reporting by independent journalist Alex Berenson is reported on his substack
A Pfizer shareholder document in October 2020 provides more evidence –
The Q3 Earnings call transcript, page 15, question from Stephen Michael Scala with Cowen and Company. Bourla’s answer follows, “Yes. Steve, I appreciate the curiosity and I appreciate the creativity, and everybody can try every possible angle, but I think I have answered this as fully as we are prepared. Now you used a very creative way of asking, so I will tell you clearly, no, we don’t have the 32 events right now. So that’s what I can say…”
https://s206.q4cdn.com/795948973/files/doc_financials/2020/q3/PFE-USQ_Transcript_2020-10-27.pdf
We recently had a group call with the US Congress head of Congressional Investigations and gave the evidence that the EUA decision was delayed.
to be continued…….
Pandemic Investigation Project 